Accordingly, the ability to prevent genital HSV infection would have major public health implications. Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD ...

MRNA vaccine pioneers BioNTech and Moderna are both trialing potential genital herpes treatment options. Their medications include prophylactics (meaning they prevent infection) and therapeutics ...

The researchers emphasize that new prevention and treatment measures such as prophylactic and therapeutic HSV vaccines “are needed critically to control HSV infections and reduce the associated ...

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

titled“Herpes Simplex Virus (Hsv) Vaccines Market” Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry ...

“HSV-1 is highly prevalent ... and studies have shown those risks can be reduced by getting a shingles vaccine. The brain-ball work suggested an explanation for how that happened; VZV creates ...

The Union budget may announce the rollout of the human papillomavirus (HPV) vaccine for cervical cancer prevention under the ...

The story of Rational Vaccines' pursuit of a therapeutic vaccine for genital herpes may go down as one of the strangest and most controversial chapters in the history of drug or vaccine development.

Cyclosporin A to inhibit CD4 T-cell-mediated immunopathology. Therapeutic vaccine designed to boost the HSV-specific CD8 T-cell response with the goal of blocking HSV reactivation and recurrent ...

Dr. Corey’s own laboratory group at Fred Hutch studies how immune cells control herpes simplex virus. Their goal is to make a vaccine that will reduce the virus’s reactivation. In the early 1980s, he ...